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doi:10.1016/j.jtcvs.2006.04.019bjective: N1 disease in non–small cell lung cancer represents a heterogeneous
atient subgroup with a 5-year survival of approximately 40%. Few reports have
valuated the correlation between N1 disease and tumor recurrence or which
ubgroup of patients would most benefit from adjuvant chemotherapy.
ethods: From 1997 through 2002, all patients with pathologic T1-4 N1 M0 non–small
ell lung cancer who had a complete resection with systematic mediastinal lymphade-
ectomy were retrospectively analyzed and evaluated for factors associated with recur-
ence and long-term survival.
esults: One hundred eighty patients with N1 disease were evaluated. Sixty-six
37%) patients had either locoregional recurrence (n 39 [22%]), distant metastasis
n  41 [23%]), or both during follow-up. Univariate analysis demonstrated that
isceral pleural invasion and age were associated with locoregional recurrence,
hereas visceral pleural invasion, distinct N1 metastasis (as opposed to direct N1
nvasion by the primary tumor), and multistation lymph node involvement were
ssociated with distant metastasis (P  .05). Multivariable analysis demonstrated
hat visceral pleural invasion, multistation N1 involvement, and distinct N1 metas-
asis were the only independent predisposing factors for locoregional recurrence and
istant metastasis. Overall 5-year survival was 42.5%. Survival was significantly
ecreased by advanced pathologic T classification (P  .015), visceral pleural
nvasion (P  .0001), and higher tumor grade (P  .014).
onclusions: In patients with N1-positive non–small cell lung cancer, visceral
leural invasion, multistation N1 disease, and distinct N1 metastasis are independent
redictors of subsequent locoregional recurrence and distant metastasis. Advanced
classification, visceral pleural invasion, and higher tumor grade were predictors of
oor survival. These patients represent a subgroup of patients with N1 disease who
ight benefit from additional therapy, including adjuvant chemotherapy.
etastasis to the N1 lymph nodes in non–small cell lung cancer (NSCLC)
portends an unfavorable prognosis, with a 5-year survival of only ap-
proximately 40%.1 N1 disease might be difficult to diagnosis preopera-
ively, despite the combined use of computed tomography and positron emission
omography, and is often first discovered at the time of pulmonary resection.2,3
urgical resection remains the recommended initial treatment of choice. A recent
andomized trial has shown a modest survival benefit with the addition of adjuvant
hemotherapy in patients with N1 disease.4 Although various factors, such as T
lassification, number and location of N1 involvement, mode of lymph node
nvolvement (direct invasion vs distinct metastasis), tumor histology, and genetic
bnormalities, have been shown to affect survival, few studies have demonstrated
ny correlation between these factors and tumor recurrence.5-11 Factors affecting
umor recurrence and long-term survival might provide insight into which subgroup
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G
TSf patients would most likely benefit from adjuvant treat-
ent. Thus the purpose of this study was to retrospectively
eview our experience with patients having completely re-
ected N1 disease and to assess factors affecting the rate and
attern of tumor recurrence and long-term survival.
atients and Methods
etween January 1997 and December 2002, 2224 patients under-
ent an anatomic complete resection (lobectomy, sleeve lobec-
omy, bilobectomy, or pneumonectomy) for primary NSCLC at the
ayo Clinic in Rochester, Minnesota. Excluded from consider-
tion were patients with a malignant pleural effusion or pleural
issemination, limited resection (wedge resection or segmentec-
omy), or induction therapy (chemotherapy, radiation therapy, or
oth). One hundred ninety-six patients underwent complete resec-
ion for pathologic T1-4 N1 M0 primary NSCLC with mediastinal
ymph node dissection, including removal of the paratracheal
stations 2 and 4), subcarinal (station 7), paraesophageal (station
), inferior pulmonary ligament (station 9), hilar (station 10), and
nterlobar (stations 11 and higher) lymph nodes. Sixteen patients
id not consent at the time of the operation to research participa-
ion. The remaining 180 patients were analyzed and form the basis
or this study.
The primary tumor histology was classified according to the
orld Health Organization classification,12 and TNM classifica-
ion was based on the revised international system for staging lung
ancer.1 The location of lymph node metastasis was defined ac-
ording to the regional lymph node classification for lung cancer
taging13 as hilar (station 10), interlobar (station 11), or intrapul-
onary (stations 12, 13, and 14). Lymph node involvement was
lso analyzed with regard to the number of metastatic lymph nodes
single vs multiple) and the mode of involvement (direct primary
umor invasion vs distinct metastasis).
Tumor recurrence was classified as either locoregional or dis-
ant. Tumor recurrence was considered locoregional if the cell type
as the same as the original and was located within the ipsilateral
emithorax, mediastinum, or supraclavicular lymph node chain.
ll other sites of recurrence were considered to be distant metas-
ases. For the purposes of analysis, 3 end points were identified:
ocoregional recurrence, distant metastasis, and any recurrence
locoregional or distant). We categorized patients in the distant
etastasis group if both locoregional recurrence and distant me-
astasis were discovered synchronously. The interval to recurrence
as defined as the interval between the time of the operation and
he discovery of the recurrence by means of either imaging or
ytopathologic examination.
Clinical data are reported as means  standard deviation or
edian (range). Cumulative survival was estimated with a Kaplan-
eier model and calculated by using the time of the operation as
he starting point.14 The comparisons of survival and survival free
Abbreviations and Acronyms
CI  confidence interval
NSCLC non–small cell lung cancerf recurrence between subgroups were investigated univariately by t
00 The Journal of Thoracic and Cardiovascular Surgery ● Septesing a Kaplan-Meier model and a Cox multivariable regression
odel.15 Univariate predictors significant at the .10 level of sig-
ificance were considered for the multivariable models. Variables
ere then eliminated from these multivariable models until all
omponents were significant at the .05 level. All tests were 2-tailed
nd performed with commercial statistical software, SAS version
.0 (SAS Inc, Cary, NC).
This study was reviewed and approved by the Mayo Founda-
ion Institutional Review Board.
esults
here were 180 patients (122 men and 58 women) with a
edian age of 67 years (range, 37-89 years). Preoperative
taging comprised a history and physical examination, con-
entional chest roentgenography, and chest and abdominal
omputed tomography. N2 disease was excluded either be-
ore thoracotomy by means of mediastinoscopy or at the
ime of thoracotomy by means of systematic mediastinal
ymphadenectomy. Clinical characteristics of these 180 pa-
ABLE 1. Patient characteristics
No. of patients
Age, y (mean  SD) 65  10
Sex
Male 122 (68%)
Female 58 (32%)
Histology
Squamous cell carcinoma 98 (54%)
Adenocarcinoma 72 (40%)
Large cell carcinoma 5 (3%)
Adenosquamous carcinoma 3 (2%)
Other 2 (1%)
Pathologic T status
T1 53 (29%)
T2 89 (49%)
T3 22 (12%)
T4 16 (9%)
Tumor location
Upper lobe 105 (58%)
Middle lobe 9 (5%)
Lower lobe 66 (37%)
Side
Right 94 (52%)
Left 86 (48%)
Operative procedure
Lobectomy 121 (67%)
Bilobectomy 13 (7%)
Pneumonectomy 46 (26%)
Tumor grade
2 10 (6%)
3 104 (58%)
4 66 (37%)
Total 180 (100%)
D, Standard deviation.ients are summarized in Table 1. There were no intraoper-
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G
TStive deaths, but 2 deaths occurred within 30 days of the
peration (operative mortality, 1.1%). Both occurred in
atients who had undergone a pneumonectomy.
Mean follow-up was 33 months (range, 0.1-92.4 months).
umor recurrence developed in 66 (37%) patients. The recur-
ences were locoregional in 25 (38%) patients, distant in 27
41%) patients, and both in 14 (21%) patients. The overall
ean interval to recurrence after the operation was 17  14
onths (range, 1-72 months), 20  15 months (range,
.3-72 months) in the locoregional group and 15  15
onths (range, 2-72 months) in the distant metastasis group.
he site of distant metastasis was the brain in 15 patients,
one in 14, the liver in 12, the contralateral lung in 6, the
drenal gland in 4, the kidney in 2, and the pancreas in 1.
he 3-year survival free of recurrence was 60%, with a 95%
onfidence interval (CI) of 52.8% to 69.0%. Overall cumu-
ative 3- and 5-year survival was 52.6% (95% CI, 45.5%-
0.9%) and 42.5% (95% CI, 35.0%-51.5%), respectively.
edian survival was 38 months.
Univariate analysis demonstrated that visceral pleural
nvasion and age were associated with locoregional re-
urrence, whereas visceral pleural invasion, distinct N1
etastasis, and multistation lymph node involvement were
ssociated with distant metastasis (P  .05, Tables 2-4).
ultivariable analysis demonstrated that visceral pleural
nvasion, multistation N1 disease, and distinct metastatic N1
nvolvement were the only independent predisposing factors
or locoregional recurrence and distant metastasis (Table 5).
Table 6 demonstrates the influence of multiple variables
n overall survival. A significant influence was observed
ith regard to T classification (P  .015, Figure 1), visceral
leural invasion by the primary tumor (P  .0001, Figure 2),
umor size (P  .0117), and tumor grade (P  .014, Figure 3).
weak association was observed between survival and the
xtent of pulmonary resection (lobectomy or bilobectomy
s pneumonectomy, P  .093), but it did not reach statis-
ical significance. No association with survival was ob-
erved with age, sex, cell type, location of tumor, involve-
ent of a hilar lymph node (station 10), number of lymph
ode stations involved, or mode of nodal involvement.
iscussion
tage I and II NSCLC has been traditionally managed with
urgical intervention alone. However, a recent randomized
rial by the International Adjuvant Lung Cancer Trial Col-
aborative group demonstrated that cisplatin-based adjuvant
hemotherapy provided a modest survival advantage in
atients with stages IB, II, and IIIA completely resected
SCLC.4 Their patient population was heterogeneous, with
9% of patients having N1 disease. The overall 5-year
urvival benefit for the entire group was only 4.1%, and the
enefit for the N1 subgroup was even smaller. Considering
hat the morbidity of adjuvant therapy could well outweigh v
The Journal of Thoraciche benefit for this group as a whole, it would be important
o identify subgroups that are more predisposed to tumor
ecurrence and reduced long-term survival for adjuvant
reatment. In our study the most significant finding was that
ABLE 2. Univariate analysis for tumor recurrence: Any
ecurrence
3-y
survival, %
95%
Confidence
interval, %
Log-rank
test,
P value
ge
65 y (n  75) 57.4 46.4-71.0 .6139
65 y (n  105) 62.8 53.0-74.4
ex
Male (n  122) 58.7 49.7-69.3 .3272
Female (n  58) 63.8 51.1-79.7
istology
Squamous (n  98) 65.9 56.3-77.2 .3935
Nonsquamous (n  82) 53.6 42.5-67.5
factor, pathologic
T1 (n  53) 67.5 55.1-82.8 .1608
T2 (n  89) 61.4 51.1-73.8
T3 (n  22) 49.8 29.1-85.3
T4 (n  16) 40.1 20.5-78.1
aterality
Right (n  94) 65.0 54.8-77.1 .0952
Left (n  86) 55.2 44.7-68.2
rimary lobe
Upper lobe (n  105) 60.8 51.2-72.1 .2810
Middle lobe (n  9) 85.7 63.3-100.0
Lower lobe (n  66) 57.2 45.2-72.4
leural invasion
With invasion (n  43) 39.7 25.7-61.4 .0003
Without invasion (n  137) 66.2 57.9-75.6
tation of nodal metastasis
Hilar (n  18) 46.2 24.7-86.4 .3910
Others (n  162) 61.6 53.7-70.5
o. of nodal stations involved
Single (n  98) 69.9 60.6-80.7 .0099
Multiple (n  82) 48.0 36.9-62.3
ode of nodal involvement
Direct invasion (n  31) 85.0 72.4-99.7 .0077
Distinct metastasis
(n  149)
55.1 46.8-65.0
umor grade
2  3 (n  114) 61.1 51.9-72.0 .1444
4 (n  66) 59.9 48.0-74.7
umor size
3 cm (n  65) 65.6 53.9-79.7 .1333
3 cm (n  115) 57.1 47.7-68.4
perative procedure
Lobectomy, bilobectomy
(n  134)
62.0 53.4-72.0 .6563
Pneumonectomy (n  46) 54.8 40.6-73.8isceral pleural invasion by the primary tumor was associ-
and Cardiovascular Surgery ● Volume 132, Number 3 501
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G
TSted with both tumor recurrence and shortened long-term
urvival. In addition, pleural invasion was a predisposing
actor for both locoregional recurrence and distant metasta-
is. Anatomically, the visceral pleura contains abundant
ABLE 3. Univariate analysis for tumor recurrence: Local
ecurrence
3-y
survival, %
95%
Confidence
interval, %
Log-rank
test,
P value
ge
65 y (n  75) 72.6 61.4-85.9 .0320
65 y (n  105) 85.9 77.1-95.8
ex
Male (n  122) 79.0 70.4-88.8 .4862
Female (n  58) 81.8 69.3-96.5
istology
Squamous (n  98) 85.7 77.2-95.0 .1817
Nonsquamous (n  82) 72.7 60.8-86.8
factor, pathologic
T1 (n  53) 85.8 74.9-98.4 .4104
T2 (n  89) 79.2 69.1-90.8
T3 (n  22) 74.7 52.2-100.0
T4 (n  16) 68.4 43.1-100.0
aterality
Right (n  94) 81.2 71.6-92.2 .4941
Left (n  86) 78.2 67.6-90.6
rimary lobe
Upper lobe (n  105) 76.3 66.7-87.2 .7795
Middle lobe (n  9) 85.7 63.3-100.0
Lower lobe (n  66) 86.4 75.6-98.7
leural invasion
With invasion (n  43) 65.5 48.7-88.2 .0024
Without invasion (n  137) 83.8 76.2-92.1
tation of nodal metastasis
Hilar (n  18) 60.0 34.7-100.0 .1186
Others (n  162) 81.6 74.2-89.7
o. of nodal stations involved
Single (n  98) 85.6 77.5-94.6 .1941
Multiple (n  82) 70.8 58.1-86.3
ode of nodal involvement
Direct invasion (n  31) 95.7 87.7-100.0 .1036
Distinct metastasis
(n  149)
76.0 67.3-85.7
umor grade
2  3 (n  114) 79.5 70.5-89.7 .5733
4 (n  66) 81.3 70.0-94.4
umor size
3 cm (n  65) 83.1 72.2-95.7 .4466
3 cm (n  115) 77.7 68.2-88.4
perative procedure
Lobectomy, bilobectomy
(n  134)
81.0 72.8-90.1 .5636
Pneumonectomy (n  46) 76.1 61.4-94.3ymphatic capillaries that form a network draining into the r
02 The Journal of Thoracic and Cardiovascular Surgery ● Septeulmonary lymphatic system. It is possible that this network
rovides a pathway for systemic micrometastasis after in-
asion by the primary cancer. If so, dissemination in such
ases might already have occurred by the time of pulmonary
ABLE 4. Univariate analysis for tumor recurrence: Distant
etastasis
3-y
survival, %
95%
Confidence
interval, %
Log-rank
test,
P value
ge
65 y (n  75) 79.1 69.5-90.0 .2995
65 y (n  105) 73.1 64.1-83.3
ex
Male (n  122) 74.3 65.9-83.7 .4845
Female (n  58) 78.0 67.3-90.5
istology
Squamous (n  98) 76.9 68.3-86.7 .9681
Nonsquamous (n  82) 73.8 63.7-85.5
factor, pathologic
T1 (n  53) 78.7 67.7-91.5 .4698
T2 (n  89) 77.6 68.6-87.7
T3 (n  22) 66.7 44.7-99.5
T4 (n  16) 58.6 36.2-95.0
aterality
Right (n  94) 80.0 71.3-89.7 .1135
Left (n  86) 70.6 60.6-82.2
rimary lobe
Upper lobe (n  105) 79.7 71.6-88.7 .0616
Middle lobe (n  9) 100.0 . . .
Lower lobe (n  66) 66.2 54.5-80.4
leural invasion
With invasion (n  43) 60.6 44.2-83.3 .0231
Without invasion (n  137) 79.0 72.0-86.7
tation of nodal metastasis
Hilar (n  18) 76.9 56.6-100.0 .9012
Others (n  162) 75.4 68.4-83.2
o. of nodal stations involved
Single (n  98) 81.7 73.6-90.6 .0240
Multiple (n  82) 67.8 57.1-80.5
ode of nodal involvement
Direct invasion (n  31) 88.9 77.7-100.0 .0350
Distinct metastasis
(n  149)
72.6 64.9-81.2
umor grade
2  3 (n  114) 76.8 68.7-85.9 .1583
4 (n  66) 73.6 62.5-86.7
umor size
3 cm (n  65) 78.9 68.9-90.3 .1900
3 cm (n  115) 73.5 64.9-83.4
perative procedure
Lobectomy, bilobectomy
(n  134)
76.6 69.0-85.0 .9098
Pneumonectomy (n  46) 72.0 58.5-88.6esection.
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G
TSThe grade of tumor differentiation was another indicator
f poor prognosis in our study. Although it did not reach
tatistical significance (P  .57 in local recurrence and P 
16 in distant metastasis), patients with tumor recurrence
ad tumors with a seemingly more aggressive grade. A
igher tumor grade was associated with poorer long-term
urvival. These observations are consistent with a report by
chinose and colleagues.16
Martini and associates17 have observed a difference in
-year survival between single (45%) and multiple (31%)
ymph nodes with N1 disease. In our study a similar trend
oward better survival in patients with single N1 disease was
ound (5-year survival, 46% vs 38%), although this differ-
nce did not attain statistical significance (P  .23).
A number of authors have reported that direct invasion of
he primary tumor to N1 lymph nodes predicted a better
rognosis compared with distinct metastatic involvement.6,18
ur study shows that distinct metastatic N1 disease, com-
ared with direct invasion of N1 lymph nodes, portends a
orse prognosis with regard to locoregional control and
istant metastatic dissemination. The survival rate of the
irect tumor invasion group was also higher, but this too did
ot reach statistical significance. Nonetheless, patients with
1 disease by direct tumor extension might represent a true
imited disease state, which might be cured with complete
urgical resection alone.
Marra and coworkers18 demonstrated that patients with
ilar lymph node (station 10) metastasis had a 5-year sur-
ival of 30%. Our data show a similar 5-year survival of
8.6%; however, this difference did not reach statistical
ignificance when compared with that seen in N1 disease at
he other stations. It has been suggested that hilar N1 disease
an be regarded as an early form of N2 disease because the
oor survival rate seen in this group is closely comparable
ABLE 5. Multivariable Cox models for recurrence analysis
ecurrence end point Variable
Odds ratio
(95% CI)
P
value
ny recurrence (local,
distant, or both)
Visceral pleural
invasion
2.4 (1.4-4.0) .0012
Multistation N1
involvement
1.8 (1.1-2.9) .0220
Distinct metastatic
N1 involvement
2.9 (1.1-7.2) .0241
ocoregional
recurrence only
Visceral pleural
invasion
3.4 (1.5-7.7) .0041
istant metastasis
(with or without
locoregional
recurrence)
Visceral pleural
invasion
2.0 (1.0-4.0) .0404
Multistation N1
involvement
1.9 (1.0-3.6) .0378
I, Confidence interval.ith that seen in patients with single-station N2 disease.19 (
The Journal of ThoracicSeveral studies have suggested that with N1 disease,
neumonectomy offers a better locoregional control than
obectomy.20,21 It is difficult to compare survival in terms of
perative procedures because several patients undergoing
neumonectomy in our series had a more advanced stage
ABLE 6. Analysis of factors affecting survival
5-y
survival, %
95%
Confidence
interval, %
Log-rank
test,
P value
ge
65 y (n  75) 44.9 33.7-60.0 .3347
65 y (n  105) 40.5 31.2-52.4
ex
Male (n  122) 39.2 30.6-50.2 .1638
Female (n  58) 50.0 37.3-67.2
istology
Squamous (n  98) 43.2 33.4-55.9 .4335
Nonsquamous (n  82) 41.4 31.0-55.5
factor, pathologic
T1 (n  53) 54.7 42.1-70.9 .0152
T2 (n  89) 42.7 32.1-56.6
T3 (n  22) 23.5 9.4-58.5
T4 (n  16) 20.3 6.3-64.9
aterality
Right (n  94) 44.8 34.8-57.8 .3037
Left (n  86) 40.0 29.9-53.5
rimary lobe
Upper lobe (n  105) 43.3 33.9-55.3 .5194
Middle lobe (n  9) 64.8 39.3-100.0
Lower lobe (n  66) 37.9 26.3-54.5
leural invasion
With invasion (n  43) 19.7 9.6-40.2 .0001
Without invasion (n  137) 49.1 40.6-59.5
tation of nodal metastasis
Hilar (n  18) 28.6 11.6-70.6 .3348
Others (n  162) 43.7 35.9-53.2
o. of nodal stations involved
Single (n  98) 46.4 36.7-58.7 .2282
Multiple (n  82) 38.0 27.6-52.2
ode of nodal involvement
Direct invasion (n  31) 51.2 35.4-74.0 .3369
Distinct metastasis
(n  149)
40.6 32.5-50.7
umor grade
2  3 (n  114) 46.6 37.2-58.4 .0141
4 (n  66) 35.3 24.5-50.9
umor size
3 cm (n  65) 53.5 41.4-69.1 .0117
3 cm (n  115) 36.3 27.6-47.7
perative procedure
Lobectomy, bilobectomy
(n  134)
45.2 36.4-56.0 .0931
Pneumonectomy (n  46) 34.5 22.4-53.1higher T classification), and the mortality for the procedure
and Cardiovascular Surgery ● Volume 132, Number 3 503
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5
G
TSs clearly known to be higher than that for a lobectomy
3.2% for pneumonectomy vs 1.2% for lobectomy).22 It is
ore reasonable to compare the locoregional recurrence
ate, which in our study showed no statistical difference
etween patients undergoing pneumonectomy and those
ndergoing either bilobectomy or lobectomy. In our opinion
obectomy is the procedure of choice for N1 disease, as long
s complete resection can be performed. Lobectomy is
ssociated with a lesser operative mortality21 and does not
ppear to increase the local recurrence rate.
It would seem that N1 disease includes 2 subgroups:
imited N1 disease with only local tumor spread that poten-
igure 1. Survival (death from any cause) by pathologic T clas-
ification (pT). Zero time on the abscissa represents the date of
he operation (P  .015).
igure 2. Survival (death from any cause) by visceral pleural
nvasion by the primary tumor. Zero time on the abscissa repre-
ents the date of the operation (P < .0001).
04 The Journal of Thoracic and Cardiovascular Surgery ● Septeially can be cured with complete surgical resection and
dvanced N1 disease with distant occult micrometastases at
he time of pulmonary resection. The inclusion of the latter
roup explains the poor survival rate of the entire N1
isease group. Our data demonstrate that visceral pleural
nvasion, multistation N1 disease, and distinct metastatic N1
nvolvement (as opposed to direct tumor extension to the N1
ymph node) were the predisposing factors for locoregional
ecurrence and distant metastasis. T classification, visceral
leural invasion, and tumor grade predicted poor long-term
urvival in patients with N1-positive NSCLC. Patients with
he above risk factors might be more likely to benefit from
djuvant systemic therapy. By defining this higher-risk
roup of patients with N1 disease, we might be better able
o tailor administration of adjuvant therapy. Overall results
f adjuvant therapy might be improved by providing treatment
or this select higher-risk group and avoiding treatment-related
njury in the completely resected N1 group that does not have
hese risk factors.
We thank Mrs Ellen Patrick for her meticulous and diligent
ranscription assistance.
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iscussion
r Eric Vallières (Seattle, Wash). There has been growing evi-
ence that adjuvant chemotherapy improves the survival of our
atients after complete resection. The IALT study referred to in
oday’s presentation was published in January of last year and
emonstrated a 4.1% improvement in survival for patients receiv-
ng platinum-based doublet chemotherapy after complete resection
f stages I, II, and IIIA non-small cell lung cancer. If you turn
hose results around, it meant that you had to treat 23 patients after
urgery to save one life. While statistically significant, this im- i
The Journal of Thoracicrovement was judged by many to be not enough to justify giving
ostop chemo, possibly toxic chemo, to all of our patients. In an
ffort to better define a subpopulation at risk for recurrence and
hus a population that should and could benefit the most from
djuvant chemotherapy, Dr. Cassivi and colleagues retrospectively
tudied the patterns of recurrence and survival in a subgroup of
80 patients with completely resected N1 disease. In a multivariate
nalysis, three descriptors were found to predict either local,
egional, or systemic recurrence: parietal pleura involvement and
istinct and/or multistation N1 nodal involvement. Survival was
ffected by pleural invasion, the higher T descriptors, the grade of
he tumor, and the size of the tumor. As a result, they recommend
onsidering a more selective use of adjuvant chemotherapy target-
ng these populations at higher risks and possibly avoiding poten-
ially toxic adjuvant treatment in the others.
Stephen, I applaud your efforts to try to better define the
opulation that we should consider for additional treatments after
urgery. This is an interesting series that confirms many of the
reviously suggested bad player descriptors.
Twenty-one percent of your study patients, however, had T3
nd T4 disease, and in my opinion it may have been more appro-
riate to try to be a little more homogeneous and to study such
atients in possibly a separate review.
I was surprised to see that the percentages of locoregional and
ystemic failures were almost identical in this Mayo series. This
ontrasts with the notion that in patients with nodal disease,
ystemic failures usually predominate. Locoregional failures were
articularly an issue when the parietal pleura was involved. Using
model of a selective approach to adjuvant therapy as you are
roposing, should we reconsider selectively studying the role of
djuvant radiation therapy in patients with parietal pleural involve-
ent where locoregional failures were so high?
Dr Cassivi. First of all, I think one of the things to clarify was
hat the pleural involvement we described was the visceral pleura.
f that was unclear in the manuscript, I apologize.
I think you are right; we too were surprised when we identified
hat locoregional recurrence was as high as distant recurrence. As
ou mentioned, our notion is that if patients fail, they fail distantly
r systemically. It does raise the question of whether better local
reatment is possible or is advisable. However, I don’t think we
ave the data necessary to advocate sending these patients to
adiation therapy at this point.
Dr Vallières. Along the same lines, you have demonstrated
hat 15 of the 41 patients who failed systemically did so at the
rain level. We know that chemotherapy has very little impact on
isease across the blood-brain barrier. Should we consider some of
hese patients for adjuvant prophylactic cranial radiation?
Dr Cassivi. We did indeed find that brain metastases show up
t a relatively high rate. My only comment on this subject is that
his demonstrates once more why lung cancer remains the most
ethal cancer. Early-stage disease in lung cancer, even when so-
alled complete resection is performed, still has a way of humbling
s. I don’t think that the data in our research presented today has
he strength, however, to advocate for prophylactic cranial radia-
ion. It doesn’t really define in which group we could expect this
o occur.
Dr Vallières. The premise for this review was that a 4.1%
mprovement in survival at five years is not a home run and that
and Cardiovascular Surgery ● Volume 132, Number 3 505
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G
TSaybe we need to be selective in offering these treatments. Yes-
erday, the New England Journal of Medicine published results of
he NCI Canada Br.10 randomized trial, which showed a 15%
mprovement in five-year survival with the use of adjuvant plati-
um vinorelbine chemotherapy after complete resection of stages
B, IIA and IIB non-small cell lung cancer. In this trial you needed
o treat 7 patients in the adjuvant setting to save one life. The
verall survival was improved by nearly 2 years in the chemother-
py arm, and if one allows a subset analysis of patients with N1
isease only, which made up 55% of the patients on that trial, their
urvival was improved by 39 months with chemotherapy. Such
esults in my opinion strongly support a less restrictive use of
djuvant chemotherapy after complete resection in good perfor-
ance-status patients. Now, 4.1% I can understand some resis-
ance; 15%, things are changing a little. I’d like you to comment.
Dr Cassivi. I would agree. It is a very timely question, because
he article has just been published while we are here in Victoria,
ritish Columbia. Dr. Winton and his multicenter collaborative
roup showed very encouraging results. Fifteen percent is not 4%.
ow this applies to the research I’ve just presented remains to be
een. I do believe, though, that this is just another example of how
e need to better identify our patients who will benefit from
djuvant therapy, either by using clinical parameters such as we’ve
sed in this research or by using other types of labels-either
olecular or other biologic markers. I think better identifying
hose patients who will improve with adjuvant therapy is still a
ital task we have to perform.
Dr Vallières. I couldn’t agree more, and just reading my notes
ere, I agree that there may be some benefits in the future of better
dentifying those who should or, probably more importantly, who
o not need to receive adjuvant chemotherapy after surgery. I also v
06 The Journal of Thoracic and Cardiovascular Surgery ● Septegree completely that the selection, however, will likely be based
ore on molecular biological descriptors of behavior than on
rude prognostic TNM factors as we have been using for too long.
thank you for this presentation. It was very well done.
Dr Cassivi. Thanks for your kind remarks.
Dr Ross Bremner (Phoenix, Ariz). Thanks very much. I
hought it was a fantastic paper and greatly presented. I was very
nterested in the percentage of squamous cell carcinomas that you
ad. I wonder if you had noticed any change in that. Our regional
istribution in Southern California now is that about 80% of the
esected cancers are adenocarcinomas, and along the lines of that,
ere you able to do any subset analysis to see whether there was
difference in the behavior of the squamous cell carcinomas and
denocarcinomas in terms of both local as well as distant failure?
Dr Cassivi. We had 54% of our patients with squamous cell
arcinoma in this series. When we analyzed by tumor histology,
e found no association with either locoregional, distant, or any
ecurrence and indeed neither with survival. Tumor histology did
ot really factor in for those outcomes. It is, however, an interest-
ng issue that again speaks to molecular markers and tumor-
pecific markers that may be of more use.
Dr. Bremner. Secondly, I just wondered if you had the oppor-
unity of looking at the degree of visceral pleural invasion as the
apanese have done and whether you have been able to see if there
re any prognostic factors from that.
Dr Cassivi. Unfortunately, the retrospective nature of this
tudy doesn’t allow us to go back to study this. We haven’t
abulated or prospectively gathered data on the degree of visceral
leural invasion. Nevertheless, a review of those classifications of
isceral pleural invasion may be of use.
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